SCHEMBL13301484

SCHEMBL13301484

CCN(CC)c1ccc(C(=O)c2ccccc2C(=O)OCC(C)(C)CC)c(O)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 5/20 0.63
▸ L3MBTL1 Q9Y468 3/20 0.63
▸ MEN1 O00255 2/20 0.63
▸ KMT2A Q03164 2/20 0.63
▸ ALDH1A1 P00352 5/20 0.50
▸ KDM4E B2RXH2 4/20 0.50
▸ GAA P10253 3/20 0.50
▸ POLB P06746 1/20 0.50
▸ TSHR P16473 2/20 0.38
▸ CDC25B P30305 1/20 0.38
▸ MAPT P10636 5/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ MAOB P27338 1/20 0.37
▸ LMNA P02545 3/20 0.37
▸ HPGD P15428 2/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ PGR P06401 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ ADORA3 P0DMS8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13301479 0.95 SMN1; SMN2 (0.66) SMN1; SMN2L3MBTL1MEN1KMT2AALDH1A1
SCHEMBL14069299 0.92 SMN1; SMN2 (0.62) SMN1; SMN2L3MBTL1MEN1KMT2AALDH1A1
SCHEMBL13301470 0.91 SMN1; SMN2 (0.66) SMN1; SMN2L3MBTL1MEN1KMT2AALDH1A1
SCHEMBL13301483 0.90 SMN1; SMN2 (0.67) SMN1; SMN2L3MBTL1MEN1KMT2AALDH1A1
SCHEMBL13301482 0.89 SMN1; SMN2 (0.58) SMN1; SMN2L3MBTL1MEN1KMT2AALDH1A1
SCHEMBL12431397 0.86 SMN1; SMN2 (0.72) SMN1; SMN2L3MBTL1MEN1KMT2AALDH1A1
SCHEMBL13301476 0.86 L3MBTL1 (0.72) SMN1; SMN2L3MBTL1MEN1KMT2AALDH1A1
SCHEMBL14529371 0.84 MEN1 (0.53) SMN1; SMN2L3MBTL1MEN1KMT2AALDH1A1
SCHEMBL12792825 0.84 SMN1; SMN2 (0.69) SMN1; SMN2L3MBTL1MEN1KMT2AALDH1A1
SCHEMBL13301485 0.84 L3MBTL1 (0.69) SMN1; SMN2L3MBTL1MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8758726-B2 Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules IMMUNOMEDICS, INC. (US) 2014-06-24 — — US disclosed
US-20100143274-A1 USE OF AMINES AND AMIDES FOR THE STABILIZATION OF ORGANIC MICRONIZED UV ABSORBERS CIBA CORPORATION (US) 2010-06-10 — — US disclosed
US-7374749-B2 Amino substituted hydroxyphenyl benzophenone derivatives CIBA SPECIALTY CHEMICALS CORP. (US) 2008-05-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100143274-A1 USE OF AMINES AND AMIDES FOR THE STABILIZATION OF ORGANIC MICRONIZED UV ABSORBERS MAOA, MAOB, ACMSD SMN1; SMN2 2903/4885L3MBTL1 4501/4885MEN1 237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback